Reactive Infectious Mucocutaneous Eruptions (RIME) in COVID-19.
Publication/Presentation Date
12-1-2023
Abstract
Reactive infectious mucocutaneous eruptions (RIME) is a relatively novel terminology describing postinfectious mucocutaneous eruptions that usually affect 2 or more mucosal sites. To our knowledge, we describe the first case of RIME secondary to COVID-19 infection in an elderly 64-year-old immunocompetent male patient. This contrasts with previous case reports that have identified cases of RIME post-COVID-19 infection among the pediatric population and young adults. Our patient had characteristic mucosal involvement and required hospitalization and treatment with systemic steroids. This report also reviews the clinical features, treatment modalities, and outcome of RIME secondary to COVID-19 infection in other published case reports. We emphasize the need for further prospective studies to better elucidate the use of steroids in the management of RIME.
Volume
122
Issue
5
First Page
368
Last Page
371
ISSN
2379-3961
Published In/Presented At
Farhan, R., Salim, S., & Surani, A. (2023). Reactive Infectious Mucocutaneous Eruptions (RIME) in COVID-19. WMJ : official publication of the State Medical Society of Wisconsin, 122(5), 368–371.
PubMedID
38180926
Department(s)
Department of Medicine
Document Type
Article